Docetaxel (Taxotere) in the treatment of non-small cell lung cancer: an international update.
Based on the results of two recent trials, docetaxel (Taxotere; Aventis, Antony, France) is now the drug of choice for the treatment of advanced non-small cell lung cancer that is refractory to primary chemotherapy. Trials are testing the role of docetaxel in the induction setting, as well as concomitantly with radiation therapy.